Fibromyalgia Study Finds Paroxetine Best of Newer Antidepressants to Combine with Drug Treatment

Fibromyalgia Study Finds Paroxetine Best of Newer Antidepressants to Combine with Drug Treatment
The combined use of pregabalin and the antidepressant paroxetine is more effective in reducing somatic symptoms and depression in fibromyalgia patients than pregabalin with other relatively new antidepressants, showing both better efficacy and tolerability and reduced side effects, according to the study, “Comparative Efficacy of Newer Antidepressants in Combination with Pregabalin for Fibromyalgia Syndrome: A Controlled, Randomized Study,” published in the journal Pain Practice. Fibromyalgia is a cause of chronic and widespread, disabling pain in young and middle-age women, and often associated with depression, anxiety, and alexithymia. In 2010, the American College of Rheumatology (ACR) established new diagnostic criteria for fibromyalgia, including a widespread pain index (WPI) and categorical scales for various cognitive and somatic symptoms, poor sleep, and fatigue. A comparison of long-term efficacy, tolerability, and safety of the concomitant use of pregabalin, an approved fibromyalgia treatment, with the antidepressant medications amitriptyline, venlafaxine, or paroxetine has not been previously studied for this disease. Eiad A. Ramzy, MBBCh, MD, FIPP Pain Clinic, Department of Anaesthesi
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *